AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,145 | -34.5% | 20,597 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $323,663 | +105.4% | 19,640 | +14.2% | 0.00% | – |
| Q1 2023 | $157,561 | +23.5% | 17,201 | -3.4% | 0.00% | – |
| Q4 2022 | $127,580 | +57.5% | 17,801 | +10.6% | 0.00% | – |
| Q3 2022 | $81,000 | +1520.0% | 16,101 | +657.3% | 0.00% | – |
| Q2 2022 | $5,000 | -66.7% | 2,126 | 0.0% | 0.00% | – |
| Q1 2022 | $15,000 | -16.7% | 2,126 | -2.9% | 0.00% | – |
| Q4 2021 | $18,000 | -14.3% | 2,189 | +1.1% | 0.00% | – |
| Q3 2021 | $21,000 | -69.6% | 2,166 | -78.8% | 0.00% | – |
| Q2 2021 | $69,000 | -31.7% | 10,213 | -8.9% | 0.00% | – |
| Q1 2021 | $101,000 | +34.7% | 11,213 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -6.2% | 11,213 | -29.7% | 0.00% | – |
| Q3 2020 | $80,000 | +66.7% | 15,951 | +165.8% | 0.00% | – |
| Q2 2020 | $48,000 | +700.0% | 6,000 | +757.1% | 0.00% | – |
| Q1 2020 | $6,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 4,133,464 | $45,592,000 | 5.54% |
| Stonepine Capital Management, LLC | 747,863 | $8,249,000 | 4.45% |
| JW Asset Management, LLC | 444,439 | $4,902,000 | 3.12% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $40,320,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 1,150,000 | $12,685,000 | 1.62% |
| FALCON POINT CAPITAL, LLC | 855,101 | $9,432,000 | 1.27% |
| Perceptive Advisors | 1,429,114 | $15,763,000 | 0.79% |
| KNOTT DAVID M | 126,463 | $1,395,000 | 0.58% |
| HEARTLAND ADVISORS INC | 700,000 | $7,721,000 | 0.50% |
| Sio Capital Management, LLC | 91,413 | $1,008,000 | 0.48% |